免疫检查点（immune checkpoint）是免疫系统中起抑制或激活作用的调节分子，对维持机体自身的免疫耐受、免疫应答的时间和免疫应激的强弱起到关键的调节作用。肿瘤细胞可以利用免疫检查点通路作为免疫逃避的主要机制，特别是逃避可以识别肿瘤特异性抗原T细胞的免疫应答。
（图片来源：Annual Review of Immunology）
目前FDA批准的几款靶向免疫检查点的抗体药都是通过阻断抑制性检查点信号通路，达到恢复T细胞的免疫应答，从而对肿瘤细胞起到杀伤作用。近年来，关于免疫检查点的抗体药物研发越来越火爆，以PD-1/PD-L1、CTLA-4为代表的抗体药物在癌症临床治疗上大放异彩，其中PD-1靶标药物在多种癌症临床治疗中达到20%-50%的响应率。随着对更多免疫检查点分子的深入研究，很多药企也开始瞄准其他免疫检查点，试图开辟出一条新的血路。
为了助力免疫检查点分子相关研究，缔码生物利用HEK293人源细胞分泌表达系统生产纯化出一批高质量的免疫检查点重组蛋白。这些在人源细胞中表达的重组蛋白具有更接近天然蛋白的二级结构和人类细胞特有的蛋白翻译后修饰。
部分产品列表
我们的长远目标是完成所有免疫检查点靶标蛋白的制备和功能验证，做到各个突破。如果您感兴趣的蛋白不在列表里，欢迎私戳我们，获得最新研发进展！
产品特点
1、聚焦于表达具有功能活性的产品
纯化重组蛋白纯度验证
Figure 1. A) Human SIRPα, hFc-His Tag on SDS-PAGE under reducing condition(PME100009). B) Human CD47, mFc-His Tag on SDS-PAGE under reducing condition(PME100008).
天然受体-配体相互作用验证
Figure 2. ELISA plate pre-coated by 2 ug/ml (100 ul/well) Human CD47, mFc-His tagged protein (PME100008) can bind its native ligand Human SIRPα, hFc-His tagged protein (PME100009) in a linear range of 3.3-26.37 ng/ml.
治疗性中和抗体结合能力验证
Figure 3. ELISA plate pre-coated by 2 ug/ml (100 ul/well) Human CD47, mFc-His tagged protein (PME100008) can bind Anti-CD47 (Neutralizing antibody clone Hu5F9-G4)(BME100001) in a linear range of 0.061-1.606 ng/ml.
2、蛋白产品质检严格
缔码生物严格把控每一批新生产的重组蛋白的质量稳定性。
多次冻融后天然受体-配体结合能力检测
Figure 4. Human SIRPα, hFc-His tagged protein without freeze-thaw treatment. B: Human SIRPα, hFc-His tagged protein after one freeze-thaw cycle. C: Human SIRPα, hFc-His tagged protein after three freeze-thaw cycles. D: Human SIRPα, hFc-His tagged protein after five freeze-thaw cycles.
多次冻融后蛋白完整性检测
Figure 5. Lane 1: Human SIRPα, hFc-His tagged protein without freeze-thaw treatment, Lane 2: Human SIRPα, hFc-His tagged protein after one freeze-thaw cycle, Lane 3: Human SIRPα, hFc-His tagged protein after three freeze-thaw cycles, Lane 4: Human SIRPα, hFc-His tagged protein after five freeze-thaw cycles.
3、好礼赠送缔码生物提供研究用重组Biosimilar抗体，您无需花费高昂的价格购买临床抗体药物即可展开药物的生物学效应研究。我们的Biosimilar抗体经过活性验证，能够很好的结合对应的靶标蛋白。
研究用Cobolimab和TIM3重组表达蛋白（PME100030）结合验证
Figure 6. ELISA plate pre-coated by 2 ug/ml (100 ul/well) Human TIM3, mFc-His tagged protein (PME100030) can bind Anti-TIM3 Neutralizing antibody (Cobolimab)(BME100008) in a linear range of 0.24-7.81 ng/ml.研究用Biosimilar重组表达抗体产品列表:
| Therapeutic Antibody | Antibody Specificity | DIMA catalog# |
| Magrolimab | Anti-CD47 mAb | BME100001 |
| Elotuzumab | Anti-CS1 mAb | BME100002 |
| Talacotuzumab | Anti-CD123 mAb | BME100003 |
| Daratumumab | Anti-CD38 mAb | BME100004 |
| Vorsetuzumab | Anti-CD70 mAb | BME100005 |
| Pembrolizumab | Anti-PD-1 mAb | BME100006 |
| Siltuximab | Anti-IL6 mAb | BME100007 |
| Cobolimab | Anti-TIM-3 mAb | BME100008 |
即日起，缔码生物推出买蛋白送对应Biosimilar抗体试用装活动，快来联系我们吧！电话：18062749453
邮箱：info@dimabio.cn
参考文献
[1]Baumeister, Susanne H., et al. “Coinhibitory pathways in immunotherapy for cancer.” Annual Review of immunology 34 (2016): 539-573.